Last reviewed · How we verify
Marevan®
Marevan is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors, thereby reducing blood coagulation.
Marevan® (warfarin) inhibits vitamin K-dependent clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Marevan® |
|---|---|
| Also known as | warfarin |
| Sponsor | Federal University of São Paulo |
| Drug class | Vitamin K antagonist (coumarin anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Marevan (warfarin) works by blocking the enzyme vitamin K epoxide reductase, which is essential for the recycling of vitamin K. This prevents the gamma-carboxylation of clotting factors II, VII, IX, and X, reducing their activity and prolonging the prothrombin time (PT/INR). The anticoagulant effect develops over several days as existing clotting factors are cleared from circulation.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Bruising
- Skin necrosis
- Warfarin-induced thrombosis
Key clinical trials
- Pharmacokinetic Drug-Drug Interaction Study of Rucaparib (PHASE1)
- Warfarin Initiation in Mechanical Mitral Valve Replacement Patients (PHASE4)
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil (PHASE4)
- Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marevan® CI brief — competitive landscape report
- Marevan® updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI